Special report: ASX-listed artificial intelligence company BrainChip has bolstered the cybersecurity capabilities of its Akida Development Environment after signing an agreement with a university in Greece.

Artificial intelligence and cybersecurity are two of the hottest areas in the technology industry.

As the ASX’s only pure artificial intelligence play, the deal offers BrainChip (ASX:BRN) investors an enticing combination.

The deal with Democritus University of Thrace sees BrainChip securing a license to the university’s cybersecurity technology and further support in porting the technology to BrainChip’s Akida Development Environment that targets the Akida Neuromorphic System-on-Chip (NsoC).

The Akida NsoC is the first announced spiking neural network architecture viable for full production.

SNNs closely mimic the human brain. ‘Neurons’ communicate through a series of spikes, with information being encoded not just in the rate of firing of the spikes, but also in their precise timing.

Democritus University of Thrace was founded in June of 1973. Professor Lazaros Iliadis said BrainChip’s Akida platform is ideal for accelerating its SNNs.

“We have been working with spiking neural networks for several years and our cybersecurity technology has proven highly accurate in detecting threats.”

Akida Neuromorphic System-on-Chip (NsoC)

Robert Beachler, BrainChip SVP of Marketing and Business Development noted the artificial intelligence cybersecurity market is estimated to be US$35B by 2025, according to MarketsandMarkets.

“As the Akida NSoC design progresses it is important that we have proven examples of SNN models and data to spike convertors for our target markets…this technology acquisition will jump-start our solutions in this lucrative application space.”

The deal’s consideration will be incurred over several quarters and will not have a material impact on BrainChip’s cash position.


BrainChip is a Stockhead advertiser.

This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice. 

If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.